Results In the biologic-nave population, secukinumab dominated adalimumab and certolizumab pegol. Incremental cost-effectiveness ratios (ICERs) versus other comparators were either below 10,000 per quality-adjusted life-year (QALY) gained or south-west ICERs that implied cost effectiveness of secukinumab...
Results In the biologic-nave population, secukinumab dominated adalimumab and certolizumab pegol. Incremental cost-effectiveness ratios (ICERs) versus other comparators were either below 10,000 per quality-adjusted life-year (QALY) gained or south-west ICERs that implied cost effectiveness of secukinumab...
(DLQI) score >10 and who have not responded to, are intolerant of, or have contraindications to traditional systemic drugs.6–9 Biologic agents commonly used for patients with moderate-to-severe disease include tumor necrosis factor inhibitors, such as adalimumab, inf- liximab, and etanercept, ...
Adalimumab treatment of life- threatening tuberculosis. Clin. Infect. Dis. 2009 May 15; 48 (10): 1429-143210.1086/598504Search in Google Scholar PubMed [14] Blackmore TK, Manning L, Taylor WJ, et al. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of ...
Objective: To evaluate the cost effectiveness of etoricoxib (90mg/day) relative to celecoxib (200 or 400mg/day), and the non-selective NSAIDs naproxen (1000mg/day) and diclofenac (150 mg/day) in the initial treatment of ankylosing spondylitis (AS) from the UK NHS perspective. ...
Use of infliximab and adalimumab from diagnosis was modelled with biosimilar costs based on average real-world UK contract drug costs ascertained from 20 PROFILE trial sites in 2024. Parameters were informed by individual patient data from PROFILE and data from the published literature. Key model ...
Background Patients with moderate-to-severe psoriasis treated with adalimumab in daily clinical practice are different from those in clinical trials, and outcomes may differ in different geographical settings. Objectives To analyse the efficacy, retention of treatment and adverse events in a cohort of ...
The cost-effectiveness of introducing apremilast before biologics was assessed from a UK payer perspective. Materials and methods : A 10-year Markov cohort model was developed to compare alternative treatment sequences: (1) apremilast followed by adalimumab and etanercept and (2) adalimumab followed ...
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an in... Rodgers,Epstein,...
PBI8 COST SAVING OPPORTUNITY TO A HEALTH-SYSTEM ADALIMUMAB BIOSIMILAR TRANSITION PROGRAMME ACCOUNT WITHIN THE UKdoi:10.1016/j.jval.2019.04.091M. WakerA. LevysohnM. BodinS. KeadyValue in Health